TET2 is a master epigenetic enzyme that converts 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), reprograming tumor cells and causing them to enter a dormant state.
Cellular senescence is a state of terminal cell cycle arrest that is being increasingly explored for its role in cancer therapeutics. Researchers from Ocean University of China reported on AS-1041, an anthraquinone compound derived from the marine compound Aspergiolide A, designed to be used against leukemia due to its pro-senescence effect.
It’s not every day you see a small drug company’s presentations get picked for both the plenary session and the late-breaker session at a conference, but Syndax Pharmaceuticals Inc. managed to do just that at the 65th American Society of Hematology Annual Meeting 2023 – with a little help from a friend.
Biomea Fusion Inc.’s diabetes treatment produced enhanced glycemic control at week 26 courtesy of its 200-mg cohort. It’s the latest advance for the company’s candidate that also has strong prospects in treating leukemia. Top-line data from the ongoing phase II Covalent-111 study of BMF-219, a covalent menin inhibitor for regenerating insulin-producing beta cells, demonstrated that about 40% of participants, four of 11 patients, in the 200-mg cohorts showed a durable reduction, 1% or more, in the amount of blood sugar attached to the type 2 diabetes (T2D) patients’ hemoglobin. The data came from participants who had received the last dose in a four-week treatment.
KAT6A is a histone acetyltransferase involved in transcriptional co-activation, proliferation and differentiation of hematopoietic progenitor and stem cells. Mutations and translocations in KAT6A are oncogenic drivers in hematological malignancies.
Nerviano Medical Sciences Srl has identified cyclin-dependent kinase 11A (CDK11A) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
A new method of CAR T-cell immunotherapy developed by researchers at the University of Pennsylvania Perelman School of Medicine could serve as a treatment for most blood cancers. Until now, CAR T-based immunotherapy for hematological malignancies has targeted the antigens CD19 for B cells, CD7 for T cells, BCMA for myeloma, and CD33 for AML.
Chengdu Easton Biopharmaceuticals Co. Ltd. has described lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Zhejiang Ocean University and affiliated organizations have reported the discovery and preclinical evaluation of a novel potent histone lysine-specific demethylase 1 (LSD1) inhibitor, FY-21, being developed for the treatment of leukemia.
After CAR T-cell immunotherapy for leukemia, some children have a longer remission because the engineered cells remain active and control or prevent the growth of new tumor cells. A new collaborative study has found that these persistent cells expressed certain genes that could be identified through a transcriptional signature. The finding could explain why the treatment does not work in some patients, and potentially help to improve it, reducing relapses.
